Online inquiry

IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11353MR)

This product GTTS-WQ11353MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Neuromyelitis optica (NMO) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, MEDI-551(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11353MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7436MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ14517MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ12624MR IVTScrip™ mRNA-Anti-ERBB2, OMNITARG™(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMNITARG™
GTTS-WQ10991MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ5085MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ11258MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ9646MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ12424MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW